Markus Dietlein

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7656376/publications.pdf

Version: 2024-02-01

42 papers	2,316 citations	279798 23 h-index	254184 43 g-index
49 all docs	49 docs citations	49 times ranked	2177 citing authors

#	Article	IF	Citations
1	An ⁸⁹Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients. Journal of Nuclear Medicine, 2022, 63, 573-583.	5.0	17
2	Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer. Molecular Imaging and Biology, 2022, 24, 115-125.	2.6	10
3	Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy â€“ Experience at a tertiary referral center. Nuklearmedizin - NuclearMedicine, 2022, 61, 314-324.	0.7	3
4	Impact of bone marrow involvement on early positron emission tomography response and progressionâ€free survival in the HD18 trial for patients with advancedâ€stage Hodgkin lymphoma. British Journal of Haematology, 2022, 197, .	2.5	0
5	[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer. Molecular Imaging and Biology, 2021, 23, 277-286.	2.6	8
6	Early Response to First-Line Antiâ€“PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial. Clinical Cancer Research, 2021, 27, 402-407.	7.0	20
7	Avoidance of iodine deficiency/excess during pregnancy in Hashimotoâ€™s thyroiditis. Nuklearmedizin - NuclearMedicine, 2021, 60, 266-271.	0.7	2
8	PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2021, 8, e398-e409.	4.6	28
9	An ¹⁸F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with ¹⁸F-JK-PSMA-7 During the First Year of Application. Journal of Nuclear Medicine, 2020, 61, 202-209.	5.0	23
10	Intraindividual Comparison of ¹⁸F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 729-734.	5.0	58
11	FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphomaâ€”An Updated Overview. Cancers, 2020, 12, 601.	3.7	33
12	AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial. Blood, 2020, 136, 31-32.	1.4	4
13	Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Research, 2019, 9, 66.	2.5	24
14	Positron Emission Tomographyâ€“Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Journal of Clinical Oncology, 2019, 37, 2835-2845.	1.6	151
15	Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma. Journal of Clinical Oncology, 2019, 37, 3324-3325.	1.6	2
16	Discovery of ¹⁸F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions. Journal of Nuclear Medicine, 2019, 60, 817-823.	5.0	41
17	Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases. EJNMMI Physics, 2018, 5, 32.	2.7	12
18	Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT. PLoS ONE, 2018, 13, e0209613.	2.5	9

#	Article	IF	Citations
19	PSA-Stratified Performance of ¹⁸F- and ⁶⁸Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 947-952.	5.0	150
20	Prostate-Specific Membrane Antigenâ€“Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 90S-96S.	5.0	48
21	Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 249-258.	6.4	49
22	Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 46-53.	0.8	23
23	Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Molecular Imaging and Biology, 2015, 17, 575-584.	2.6	288
24	Developments in oncological positron emission tomography/computed tomography assessment. Journal of Thoracic Disease, 2015, 7, E637-9.	1.4	0
25	Development of hypothyroidism during longâ€term followâ€up of patients with toxic nodular goitre after radioiodine therapy. Clinical Endocrinology, 2012, 76, 297-303.	2.4	24
26	Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?. Nuclear Medicine Communications, 2010, 31, 201-205.	1.1	45
27	EANM procedure guidelines for therapy of benign thyroid disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2218-2228.	6.4	174
28	Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Nuklearmedizin - NuclearMedicine, 2010, 49, 97-105.	0.7	8
29	Radioiodine therapy for thyroid volume reduction of large goitres. Nuclear Medicine Communications, 2009, 30, 466-471.	1.1	26
30	FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in Hodgkin Lymphoma - Report on the 2nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG.. Blood, 2007, 110, 212-212.	1.4	6
31	Incidence of Postradioiodine Immunogenic Hyperthyroidism/Graves' Disease in Relation to a Temporary Increase in Thyrotropin Receptor Antibodies After Radioiodine Therapy for Autonomous Thyroid Disease. Thyroid, 2006, 16, 281-288.	4.5	42
32	Incidental multifocal papillary microcarcinomas of the thyroid: Is subtotal thyroidectomy combined with radioiodine ablation enough?. Nuclear Medicine Communications, 2005, 26, 3-8.	1.1	37
33	Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. European Journal of Haematology, 2005, 74, 348-352.	2.2	38
34	Monitoring of Tumor Response to Neoadjuvant Radio-Chemotherapy of Esophageal Carcinoma by F-18-FDG-PET. Chinese-German Journal of Clinical Oncology, 2004, 3, 257-262.	0.1	0
35	Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1671-1676.	2.1	146
36	Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: anin-vitro31P high-resolution NMR study. NMR in Biomedicine, 2000, 13, 8-13.	2.8	33

#	Article	IF	Citations
37	Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1441-1456.	2.1	62
38	Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1598-1609.	6.4	119
39	Iterative reconstruction: an improvement of technetium-99m MIBI SPET for the detection of parathyroid adenomas?. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 485-489.	6.4	22
40	Economic evaluation studies in nuclear medicine: the need for standardization. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 663-680.	6.4	22
41	Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1547-1552.	6.4	276
42	Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 1342-1348.	6.4	167